Respiratory Medicine
Volume 104, Issue 10 , Pages 1417-1424 , October 2010

Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction

Received 15 November 2009 ,Accepted 14 April 2010.

References 

  1. GINA NHLBI/WHO workshop report 1995. Global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995;Updated April, 2002. Publication No 95-3659 (Scientific information and recommendations for asthma programs. NIH Publication No 02-3659)
  2. Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes ES. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thorac Soc. 2004;1:235–238
  3. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol. 2006;118:789–798
  4. Echazarreta AL, Dahlén B, García G, et al. Pulmonary gas exchange and sputum cellular responses to inhaled leukotriene D(4) in asthma. Am J Respir Crit Care Med. 2001;164(2):202–206
  5. Mulder A, Gauvreau GM, Watson RM, O’Byrne PM. Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med. 1999;159:1562–1567
  6. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med. 2000;161:9–16
  7. Wenzel SE, Szefler SJ, Leung DY, et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156:737–743
  8. van den Berge M, Polosa R, Kerstjens HA, Postma DS. The role of endogenous and exogenous AMP in asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2004;114:737–746
  9. van den Berge M, Meijer RJ, Kerstjens HAM, et al. PC20 adenosine 5′-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacoline. Am J Respir Crit Care Med. 2001;163:1546–1550
  10. Choi SH, Kim DK, Yu J, Yoo Y, Koh YY. Bronchial responsiveness to methacholine and adenosine 5′-monophosphate in young children with asthma: their relationship with blood eosinophils and serum eosinophil cationic protein. Allergy. 2007;62:119–124
  11. Prieto L, Bruno L, Gutiérrez V, et al. Airway responsiveness to adenosine 5′-monophosphate and exhaled nitric oxide measurements. Predictive value as markers for reducing the dose of inhaled corticosteroids in asthmatic subjects. Chest. 2003;124:1325–1333
  12. van den Berge M, Kerstjens HA, Meijer RJ, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med. 2001;164:1127–1132
  13. Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. Ann Allergy Asthma Immunol. 2009;103:363–369
  14. Prosperini G, Rajakulasingam K, Cacciola RR, et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. J Allergy Clin Immunol. 2002;110:855–861
  15. Doull IJ, Sandall D, Smith S, Schreiber J, Freezer NJ, Holgate ST. Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5′ monophosphate, methacholine, and bradikinin in symptomatic children with recurrent wheeze. Pediatr Pulmonol. 1997;23:404–411
  16. Ketchell RI, Jensen MW, Lumley P, Wright AM, Allenby MI, O’Connor BJ. Rapid effect of fluticasone propionate on airway responsiveness to adenosine 5′ monophosphate in mild asthma. J Allergy Clin Immunol. 2002;110:603–606
  17. Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers JW. Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction. Eur Respir J. 2004;23:559–564
  18. Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005;18:328–336
  19. Moeller A, Lehmann A, Knauer N, Albisetti M, Rochat M, Johannes W. Effects of montelukast on subjective and objective outcome measures in preschool asthmatic children. Pediatr Pulmonol. 2008;43:179–186
  20. Lee DK, Jackson CM, Haggart K, Lipworth BJ. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest. 2004;125:1372–1377
  21. Rorke S, Jennison S, Jeffs JA, Sampson AP, Arshad H, Holgate ST. Role of cysteinyl leukotrienes in adenosine 5′-monophosphate induced bronchoconstriction in asthma. Thorax. 2002;57:323–327
  22. Currie GP, Haggart K, Lee DK, et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy. 2003;783–788
  23. Joos GF, O’Connor B, Anderson SD, et al. ERS Task Force. Indirect airway challenges. Eur Respir J. 2003;21:1050–1068
  24. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med. 2000;161:309–329
  25. Polosa R, Ciamarra I, Mangano G, et al. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J. 2000;15:30–35
  26. Kippelen P, Larsson J, Anderson SD, et al. Acute effects of beclomethasone on hyperpnea-induced bronchoconstriction. Med Sci Sports Exerc. 2010;42:273–280
  27. Markham A, Faulds D. Montelukast. Drugs. 1998;56:251–256
  28. Crimi N, Pagano C, Palermo F, et al. Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin A-induced bronchoconstriction. J Allergy Clin Immunol. 2003;111:833–839
  29. Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol. 2008;153(Suppl. 1):S446–S456
  30. van den Berge M, Kerstjens HA, de Reus DM, Koëter GH, Kauffman HF, Postma DS. Provocation with adenosine 5′-monophosphate, but not methacholine, induces sputum eosinophilia. Clin Exp Allergy. 2004;34:71–76
  31. Bucchioni E, Csoma Z, Allegra L, Chung KF, Barnes PJ, Kharitonov SA. Adenosine 5′-monophosphate increases levels of leukotrienes in breath condensate in asthma. Respir Med. 2004;98:651–655
  32. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med. 2003;167:1232–1238
  33. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med. 1999;160:1862–1868
  34. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ. Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest. 2001;119:1021–1026
  35. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with antagonist or low dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol. 2002;109:68–74
  36. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma. A randomized controlled trial. Am J Respir Crit Care Med. 2001;163:32–36
  37. Linden M, Svensson C, Andersson M, Greiff L, Persson CGA. Immediate effect of topical budesonide on allergen challenge-induced nasal mucosal fluid levels of granulocyte-macrophage colony-stimulating factor and interleukin-5. Am J Respir Crit Care Med. 2000;30:51–54
  38. Thio BJ, Slingerland GL, Nagelkerke AF, Roord JJ, Mulder PG, Dankert-Roelse JE. Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. Pediatr Pulmonol. 2001;32:115–121
  39. Kumar SD, Brieva JL, Danta J, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med. 2000;161:918–921
  40. Verrière VA, Hynes D, Faherty S, et al. Rapid effects of dexamethasone on intracellular pH and Na+/H+ exchanger activity in human bronchial epithelial cells. J Biol Chem. 2005;280:35807–35814
  41. Zhou J, Liu DF, Liu C, et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. Allergy. 2008;63:1177–1185
  42. Lipworth BJ. Leukotriene-receptor antagonists. Lancet. 1999;353:57–62
  43. Gyllfors P, Dahlén SE, Kumlin M, Larsson K, Dahlén B. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J Allergy Clin Immunol. 2006;118:78–83
  44. Dempsey OJ, Wilson AM, Sims EJ, Mistry C, Lipworth BJ. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest. 2000;117:950–953
  45. Çýllý A, Kara A, Özdemir T, Öğüş C, Gülkesen KH. Effects of oral montelukast on airway function in acute asthma. Resp Med. 2003;97:533–536
  46. Camargo CA, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003;167:528–533
  47. Camargo CA, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol. 2010;125:374–380

PII: S0954-6111(10)00193-9

doi: 10.1016/j.rmed.2010.04.014

Respiratory Medicine
Volume 104, Issue 10 , Pages 1417-1424 , October 2010

Article Tools

* Image Usage & Resolution